TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01454843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK - Allegretto
Description: Wavefront-guided LASIK using the Allegretto excimer laser for myopia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront-guided LASIK - AMO
Description: Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
Study: NCT03067675

Intervention type: DEVICE
Intervention: Topcon DRI OCT Triton (plus)
Description: OCT Machine used for diagnostic purposes
Study: NCT02672332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Placebo comparator
Study: NCT00201240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ selection with CliniMACS device
Description: CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
Study: NCT01793688

Intervention type: DRUG
Intervention: Sulbactam Sodium/Ampicillin Sodium
Description: Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
Study: NCT03379844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Description: An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
Study: NCT00715104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T with Booster
Description: Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T without Booster
Description: Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
Study: NCT02781181

Intervention type: DEVICE
Group type: OTHER
Intervention: CAS with CPD
Description: using a neuroprotection device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAS without CPD
Description: No Neuroprotection
Study: NCT02132975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsies using Apollo and UroStation®
Description: Apollo : Motorised probe handler for prostate biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies using UroStation® (image fusion)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies using UroStation® (image fusion)
Study: NCT00919997

Intervention type: GENETIC
Intervention: DNA analysis
Description: Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.

Intervention type: OTHER
Intervention: fluorescence activated cell sorting
Description: Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
Study: NCT02542800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic memory task
Study: NCT00919997

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.

Intervention type: PROCEDURE
Intervention: study of high risk factors
Description: Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
Study: NCT03595813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy collection
Description: Optional biopsy collection at baseline and progression
Study: NCT02222831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 0 denudation and time lapse culture on IVF-oocytes.
Study: NCT04326868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzimidazole Anthelmintic
Description: The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzimidazole Anthelmintic
Description: The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzimidazole Anthelmintic
Description: The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
Study: NCT01903785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01618851

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with IMRT and CyberKnife Boost
Description: Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions.
Study: NCT02941796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0816
Study: NCT01451138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Study: NCT00800813

Intervention type: BEHAVIORAL
Intervention: Penile Exam, Peyronie's Plaque and Erectile function assessment
Description: At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level.
Study: NCT02622841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BLEND
Description: Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
Study: NCT02542800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Study: NCT02178397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERLOTINIB WITH CHEMOTHERAPY

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHEMOTHERAPY ONLY
Study: NCT01501747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine, paracetamol, cephalexin, or ibuprofen
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)
Description: The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
Study: NCT04608032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder
Description: The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery-Oriented Therapy
Description: The second group will have \[THoR\] Recovery-Oriented Therapy
Study: NCT03357471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: e-Device
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: e-Device
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device
Study: NCT04832581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Self-Care Behavior Development Program
Description: This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
Study: NCT04420741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Continuously infusion for 72 hours at 3 ml/hours
Study: NCT01145417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 150 mg-600 mg/day (twice daily)
Study: NCT02671578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
Study: NCT02435797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
Study: NCT02435381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carisbamate
Description: 600mg Orally on days 2-4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment only
Study: NCT02156388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection
Study: NCT04239157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC
Study: NCT04585737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir / Lamivudine Pill
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Description: Active comparator
Study: NCT02375932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Visit Tool
Description: Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Patients continue to receive usual care from their primary care provider
Study: NCT00793299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Illness Narrative
Description: video
Study: NCT02499835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP Plasmid DNA Vaccine
Description: Given ID
Study: NCT00666835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa Hexal AG
Description: HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO®, Janssen-Cilag
Description: Solution for i.v. injection
Study: NCT03972137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Smoking Cessation
Description: Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Description: All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
Study: NCT01906658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
Study: NCT00529555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline HCl 2.1%
Description: Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing
Study: NCT03226353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Description: contact lens
Study: NCT03974451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of of PhysIOL trifocal FineVision® POD F IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
Study: NCT03317899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo auto HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo auto HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study: NCT03168425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored prescription
Description: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will be prescribed 30 tablets of oxycodone 5mg